Jiangsu Hengrui Pharmaceuticals Hits Day High with 4.47% Surge

Jiangsu Hengrui Pharmaceuticals Co., Ltd. has experienced a notable increase of 4.47% on July 20, 2026, reaching an intraday high of CNY 55.78. This performance stands out against the backdrop of the China Shanghai Composite, which rose by only 0.85% on the same day. Over the past month, Jiangsu Hengrui has shown a robust gain of 14.77%, contrasting with the Shanghai Composite's decline of 7.19%. However, the stock's year-to-date performance remains negative at -6.71%, slightly underperforming the broader market index, which is down 4.35%. Despite the recent uptick, the company has faced challenges in long-term growth, with net sales and operating profit growing at annual rates of 3.76% and 4.45%, respectively, over the last five years. The stock's valuation reflects a price-to-book ratio of 4.60 and a return on equity of 12.33%. Additionally, the company maintains a dividend yield of 0.44%, appealing to income-focused investors. Overall, Jiangsu Hengrui's performance metrics indicate a complex landscape for the pharmaceutical giant.